Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer

Annals of Oncology

Volumn 20, Issue 3, 2009, Pages 498-502

  Spitaleri, Gianluca ^a   Matei, D V ^a   Curigliano, G ^a   Detti, S ^a   Verweij, F ^a   Zambito, S ^a   Scardino, E ^a   Rocco, B ^a   Nole F ^a   Ariu, L ^a   De Pas, T ^a   de Braud, F ^a   De Cobelli, O ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Estramustine phosphate; Etoposide; Hormone refractory prostate cancer

Indexed keywords

ESTRAMUSTINE; ETOPOSIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; HYPERSALIVATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RETROSTERNAL PAIN; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; VOMITING; WEIGHT REDUCTION;

EID: 61649122577     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn650     Document Type: Article

References (30)

1. Tannock IF, de Wit R, Berry WR et al. TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-1512.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-1520.
3. Hudes GR, Nathan FE, Khater C et al. Paclitaxel plus estramustine in metastatic hormone-refractory prostrate cancer. Semin Oncol 1995; 22 (5 Supp. 12):41-45.
4. Hudes GR, Nathan F, Khater C et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15(9): 3156-3163.
5. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: A final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19(9): 2509-2516.
6. Sitka Copur M, Ledakis P, Lynch J et al. Weekly docetaxel and estramustine in patients with hormone-refractory prostrate cancer. Semin Oncol 2001; 28 (4 Suppl 15):16-21.
7. Kuruma H, Fujita T, Shitara T et al. Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: A pilot study. Int J Urol 2003; 10(9): 470-475.
8. Safarinejad MR. Combination chemotherapy with docetaxel, estramustine and suramin for hormone refractory prostate cancer. Urol Oncol 2005; 23(2): 93-101.
9. Segawa T, Kamoto T, Kinoshita H et al. Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostrate cancer. Int J Clin Oncol 2005; 10(5): 333-337.
10. Kikuno N, Urakami S, Nakamura S et al. Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer. Eur Urol 2007; 51(5): 1252-1258.
11. Hudes G, Einhorn L, Ross E et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol 1999; 17(10): 3160-3166.
12. Bracarda S, Tonato M, Rosi P et al. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: A phase II study. Cancer 2000; 88(6): 1438-1444.
13. Nishimura K, Nonomura N, Ono Y et al. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology 2001; 60(1): 49-54.
14. Borrega P, Velasco A, Bolaños M et al. Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urol Oncol 2004; 22(1): 32-35.
15. Kaku H, Saika T, Tsushima T et al. Combination chemotherapy with estramustine phosphate, ifosfamide and cisplatin for hormone-refractory prostate cancer. Acta Med Okayama 2006; 60(1): 43-49.
16. Nakabayashi M, Ling J, Xie W et al. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer. Cancer J 2007; 13(2): 125-129.
17. Hirano D, Minei S, Kishimoto Y et al. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy. Urol Int 2005; 75(1): 43-49.
18. Maulard-Durdux C, Dufour B, Hennequin C et al. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer 1996; 77(6): 1144-1148.
19. Odrazka K, Vaculikova M, Petera J et al. Bi-weekly epirubicin, etoposide and low dose dexamethasone for hormone-refractory prostrate cancer. Int J Urol 2003; 10(7): 387-391.
20. Pienta KJ, Redman B, Hussain M et al. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 1994; 12(10): 2005-2012.
21. Dimopoulos MA, Panopoulos C, Bamia C et al. Oral estramustine and oral etoposide for hormone-refractory prostrate cancer. Urology 1997; 50(5): 754-758.
22. Dimopoulos MA, Kiamouris C, Gika D et al. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: A randomized phase II study. Urology 2004; 63(1): 120-125.
23. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3): 205-216.
24. CTC Version 2.0. http://www.pharmadhoc.com/NCI%20CTC.htm (3 May 2008, date last accessed).
25. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38(1): 143-151.
26. Kaplan EL, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-461.
27. Lubiniecki GM, Berlin JA, Weinstein RB, Vaughn DJ. Thromboembolic events with estramustine phosphate-based chemotherapy in patients with hormone-refractory prostate carcinoma: Results of a meta-analysis. Cancer 2004; 101(12): 2755-2759.
28. Nelius T, Klatte T, Yap R et al. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer. BJU Int 2006; 98(3): 580-585.
29. Eymard JC, Priou F, Zannetti A et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol 2007; 18(6): 1064-1070.
30. Garcia JA, Weinberg V, Small EJ. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clin Prostate Cancer 2005; 4(2): 113-117.